# Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

> **NCT01508026** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 4161 (actual)

## Conditions studied

- Stage 1 Hypertension
- Stage 2 Hypertension

## Interventions

- **DRUG:** Nebivolol and Valsartan 1
- **DRUG:** Nebivolol and Valsartan 2
- **DRUG:** Nebivolol and Valsartan 3
- **DRUG:** Nebivolol 1
- **DRUG:** Nebivolol 2
- **DRUG:** Valsartan 1
- **DRUG:** Valsartan 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01508026
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-03
- **Final completion:** 2013-05
- **Target enrollment:** 4161 (ACTUAL)
- **Last updated:** 2014-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508026, "Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01508026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*